Qi Lu Wan Bao·2026-02-05 07:00Core Insights - The article discusses the approval of a new BCL2 inhibitor, Baiyueda (Sotuklara), by the National Medical Products Administration in China for treating chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and relapsed or refractory mantle cell lymphoma (MCL) patients, marking a significant advancement in the treatment of blood cancers in China [1][4][6]. Industry Overview - Blood cancers, including lymphomas, multiple myeloma, and leukemia, have shown a significant increase in incidence, with lymphomas now being the most common type of blood cancer in China [2][3]. - The rise in cases is particularly notable among older populations, with chronic lymphocytic leukemia and mantle cell lymphoma seeing a marked increase in diagnoses [2]. Treatment Advancements - Traditional treatment methods for CLL and SLL have evolved, with chemotherapy being replaced by targeted therapies such as BTK inhibitors, which have shown superior efficacy [3][4]. - The introduction of BCL2 inhibitors, particularly Sotuklara, represents a breakthrough in treatment, offering new options for patients who are not suitable for chemotherapy [4][5]. Mechanism and Efficacy - BCL2 inhibitors work by specifically binding to and inhibiting the BCL2 protein, which prevents cancer cells from undergoing apoptosis, thus promoting cell death in blood cancers [6]. - Sotuklara has demonstrated strong efficacy and safety in preliminary clinical trials, providing a new treatment pathway for patients with relapsed or refractory conditions [4][5]. Future Potential - The potential of BCL2 inhibitors lies in their ability to shift treatment paradigms from continuous therapy to limited-duration treatment, allowing for deep molecular remissions and potentially long-term disease-free survival [6][7]. - The treatment goals for CLL and MCL have evolved from merely controlling the disease to achieving deep molecular remissions and exploring potential cures [7]. Market and Accessibility - The approval of innovative drugs like Sotuklara signifies China's progress in the blood cancer treatment landscape, moving from a follower to a leader in the field [8]. - Ensuring patient access to these new therapies is crucial, with calls for the inclusion of such drugs in national insurance schemes to alleviate financial burdens on patients [8][9]. Clinical Leadership - The Shandong University Qilu Hospital's hematology department is recognized as a national center for lymphoma treatment, contributing significantly to the development and application of new therapies [10][11]. - The department aims to enhance the quality of care and expand access to innovative treatments for patients in the region [11].